Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Total Current Liabilities: 2013-2025

Historic Total Current Liabilities for Fortress Biotech (FBIO) over the last 13 years, with Sep 2025 value amounting to $54.1 million.

  • Fortress Biotech's Total Current Liabilities fell 23.10% to $54.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.1 million, marking a year-over-year decrease of 23.10%. This contributed to the annual value of $71.4 million for FY2024, which is 15.91% down from last year.
  • Per Fortress Biotech's latest filing, its Total Current Liabilities stood at $54.1 million for Q3 2025, which was down 6.00% from $57.5 million recorded in Q2 2025.
  • Fortress Biotech's 5-year Total Current Liabilities high stood at $129.5 million for Q1 2023, and its period low was $53.8 million during Q1 2021.
  • Moreover, its 3-year median value for Total Current Liabilities was $75.5 million (2024), whereas its average is $84.6 million.
  • Per our database at Business Quant, Fortress Biotech's Total Current Liabilities soared by 176.85% in 2021 and then plummeted by 41.25% in 2024.
  • Over the past 5 years, Fortress Biotech's Total Current Liabilities (Quarterly) stood at $101.0 million in 2021, then rose by 26.40% to $127.7 million in 2022, then tumbled by 33.52% to $84.9 million in 2023, then declined by 15.91% to $71.4 million in 2024, then declined by 23.10% to $54.1 million in 2025.
  • Its last three reported values are $54.1 million in Q3 2025, $57.5 million for Q2 2025, and $73.7 million during Q1 2025.